OBJECTIVE: The early application of cognitive rehabilitation may afford long-term functional benefits to patients with schizophrenia. This study examined the two-year effects of an integrated neurocognitive and social-cognitive rehabilitation program, cognitive enhancement therapy (CET), on cognitive and functional outcomes in early-course schizophrenia. METHODS:Early-course outpatients (mean+/-SD illness duration=3.19+/-2.24 years) with schizophrenia or schizoaffective disorder were randomly assigned to CET (N=31) or enriched supportive therapy (EST) (N=27), an illness management intervention utilizing psychoeducation and applied coping strategies, and treated for two years. Multivariate composite indexes of cognitive, social adjustment, and symptom domains were derived from assessment batteries administered annually by computer-based tests and raters not blind to treatment assignment. RESULTS: Of the 58 participants who were randomly assigned and treated, 49 and 46 completed one year and two years of treatment, respectively. Intent-to-treat analyses showed significant differential effects favoring CET on social cognition, cognitive style, social adjustment, and symptomatology composites during the first year of treatment. After two years, moderate effects (d=.46) were observed favoring CET for enhancing neurocognitive function. Strong differential effects (d>1.00) on social cognition, cognitive style, and social adjustment composites remained at year 2 and also extended to measures of symptomatology, particularly negative symptoms. CONCLUSIONS:CET appears to be an effective approach to the remediation of cognitive deficits in early schizophrenia that may help reduce disability in this population. The remediation of such deficits should be an integral component of early intervention programs treating psychiatrically stable schizophrenia outpatients.
RCT Entities:
OBJECTIVE: The early application of cognitive rehabilitation may afford long-term functional benefits to patients with schizophrenia. This study examined the two-year effects of an integrated neurocognitive and social-cognitive rehabilitation program, cognitive enhancement therapy (CET), on cognitive and functional outcomes in early-course schizophrenia. METHODS: Early-course outpatients (mean+/-SD illness duration=3.19+/-2.24 years) with schizophrenia or schizoaffective disorder were randomly assigned to CET (N=31) or enriched supportive therapy (EST) (N=27), an illness management intervention utilizing psychoeducation and applied coping strategies, and treated for two years. Multivariate composite indexes of cognitive, social adjustment, and symptom domains were derived from assessment batteries administered annually by computer-based tests and raters not blind to treatment assignment. RESULTS: Of the 58 participants who were randomly assigned and treated, 49 and 46 completed one year and two years of treatment, respectively. Intent-to-treat analyses showed significant differential effects favoring CET on social cognition, cognitive style, social adjustment, and symptomatology composites during the first year of treatment. After two years, moderate effects (d=.46) were observed favoring CET for enhancing neurocognitive function. Strong differential effects (d>1.00) on social cognition, cognitive style, and social adjustment composites remained at year 2 and also extended to measures of symptomatology, particularly negative symptoms. CONCLUSIONS:CET appears to be an effective approach to the remediation of cognitive deficits in early schizophrenia that may help reduce disability in this population. The remediation of such deficits should be an integral component of early intervention programs treating psychiatrically stable schizophrenia outpatients.
Authors: Michael F Green; Keith H Nuechterlein; James M Gold; Deanna M Barch; Jonathan Cohen; Susan Essock; Wayne S Fenton; Fred Frese; Terry E Goldberg; Robert K Heaton; Richard S E Keefe; Robert S Kern; Helena Kraemer; Ellen Stover; Daniel R Weinberger; Steven Zalcman; Stephen R Marder Journal: Biol Psychiatry Date: 2004-09-01 Impact factor: 13.382
Authors: Gerard E Hogarty; Samuel Flesher; Richard Ulrich; Mary Carter; Deborah Greenwald; Michael Pogue-Geile; Matcheri Kechavan; Susan Cooley; Ann Louise DiBarry; Ann Garrett; Haranath Parepally; Rebecca Zoretich Journal: Arch Gen Psychiatry Date: 2004-09
Authors: Shaun M Eack; Catherine G Greeno; Michael F Pogue-Geile; Christina E Newhill; Gerard E Hogarty; Matcheri S Keshavan Journal: Schizophr Bull Date: 2008-07-22 Impact factor: 9.306
Authors: Richard S E Keefe; Larry J Seidman; Bruce K Christensen; Robert M Hamer; Tonmoy Sharma; Margriet M Sitskoorn; Richard R J Lewine; Deborah A Yurgelun-Todd; Ruben C Gur; Mauricio Tohen; Gary D Tollefson; Todd M Sanger; Jeffrey A Lieberman Journal: Am J Psychiatry Date: 2004-06 Impact factor: 18.112
Authors: William S Stone; Xiaolu Hsi; Liwen Tan; Shaochun Zhu; Lingjiang Li; Anthony J Giuliano; Larry J Seidman; Ming T Tsuang Journal: Asian J Psychiatr Date: 2012-03
Authors: V Shashi; W Harrell; S Eack; C Sanders; A McConkie-Rosell; M S Keshavan; M J Bonner; K Schoch; S R Hooper Journal: J Intellect Disabil Res Date: 2015-04-14
Authors: Keith H Nuechterlein; Joseph Ventura; Kenneth L Subotnik; Jacqueline N Hayata; Alice Medalia; Morris D Bell Journal: Am J Psychiatr Rehabil Date: 2014-07
Authors: Jimmy Choi; Cheryl M Corcoran; Joanna M Fiszdon; Michael Stevens; Daniel C Javitt; Melissa Deasy; Lawrence C Haber; Michael J Dewberry; Godfrey D Pearlson Journal: Psychiatr Rehabil J Date: 2016-08-25